In developing countries, the cost of vaccination limits the use of prophylactic rabies vaccination, especially in cattle. Intradermal vaccination delivers antigen directly to an area with higher number of antigen-presenting cells. Therefore, it could produce equivalent or higher antibody titres than conventional intramuscular vaccination even when a lower dose is given.
This study aimed to compare the antibody response in cattle vaccinated intramuscularly with 1mL of inactivated rabies vaccine (Raksharab, Indian Immunologicals) against intradermally vaccinated cattle with 0.2mL of the same vaccine. The study was conducted in Haa province of Bhutan where rabies is not endemic. One hundred cattle from 27 farms were selected for the study. Virus neutralising antibody (VNA) response was measured using the fluorescent antibody virus neutralisation test on the day of vaccination (day 0) and 14, 30, 60 and 90 days later.
Overall, 71% of intradermally vaccinated cattle and 89% of the intramuscularly vaccinated cattle produced a protective response (≥0.5IU/mL). This difference was significant (P<0.02) on days 14 and 30 post vaccination with 36 and 58% in the intradermal group having titres ≥0.5 IU/mL respectively compared to the equivalent figures of 78 and 77% in the intramuscular group. The mean VNA titres were lower for intradermal group than intramuscular group (p<0.001) with the mean difference being greater than 0.6 IU/mL. Although low dose intradermal vaccination did produce a detectable antibody response, it was inferior to intramuscular vaccination. Thus, although intradermal vaccination has the potential to reduce the cost of vaccination by reducing the dose required, this study showed that a single dose of 0.2mL intradermally was inferior to an intramuscular dose of 1mL. Further research evaluating dose and dose regimen is needed before intradermal vaccination using the Raksharab rabies vaccine can be recommended in cattle.
Introduction 36
Rabies is a fatal zoonotic viral disease inducing an acute disease of the central nervous 37 system in almost all mammals (1). In cattle, rabies causes significant economic losses to 38 livestock farmers (2-5) principally through increasing mortality, decreasing bodyweight and 39 milk production. Furthermore, costs of euthanasia, diagnosis, replacement and vaccination of 40 at risk herds add to the loss (6, 7) . 41 In Bhutan, rabies is endemic in 29% of the country (8) with the dog being the principle vector 42 and reservoir host. Cattle contract the disease as a spill-over infection from dogs; nevertheless 43 over 80% of the economic loss due to rabies in Bhutan is due to cattle deaths (9). The 44 extensive grazing system (>60% of farms (10), free movement of cattle around their 45 compound (>70%) and limited restrictions on access even when they are housed increase the 46 risk of cattle contracting rabies from rabid dogs (11). This risk is exacerbated by the large number of dogs in Bhutan ( dog population estimated at 120 000 dogs, equivalent to one dog Animal selection 126 A minimum of four cattle per farm was required to get a final sample of 100 animals from 25 127 farms. However, on the day of vaccination, 12 of the pre-selected farms had less than four 128 cattle in their herd, so extra farms that were located near to the pre-selected farms were used 129 in addition to the original 25 farms to reach the target of at least 90 vaccinated cattle. In addition, on four farms more than four cattle were selected as four of the pre-selected farms 131 practised the transhumant system of rearing. Only animals of age six months and above were 132 eligible for selection in order to avoid any interference from maternal antibodies. On each 133 farm, cattle were randomly assigned to treatment using a random allocation table. Ninety 134 animals were designated for treatment 'A' or treatment 'B with 45 cattle in each treatment 135 group. Ten cattle were kept as controls.
136
The age, body condition score (BCS) (0-5 scale) (21) and breed of the selected cows were 137 recorded. Age ranged from 6 months to 15 years, BCS from 2-3, and the selected animals 138 included a mixture of local, Jersey, Jersey cross and Holstein Friesian breeds.
139

Vaccination
140
Selected cattle were given either 1 mL of rabies vaccine (22) intramuscularly into the middle 141 third of the neck, or 0.2 mL of the same vaccine intradermally at the same site. The vaccine 142 used was an inactivated cell culture vaccine authorised for intramuscular or subcutaneous use 143 in cattle, dogs and cats (Raksharab company data). Potency testing at the OIE/EU/WHO 144 reference laboratory on Rabies, Nancy, France showed that the vaccine used in the study had 145 a potency of 8.5 IU/mL (Limits 2.2 to 37.4 IU/mL), greater than the recommended minimum 146 of 1 IU/dose (23, 24) .
147
On farms that had more than four cattle a control cow was selected for blood sampling but 148 not vaccination. These control animals were equally distributed across the three selected sub 149 districts.
150
All animals, irrespective of treatment group were managed as normal by the owners who 151 were blinded to treatment allocation. Cattle on 17 of the 27 farms were housed permanently 152 during the winter and stall fed; on 10 farms cattle were sent for grazing during the daytime in 153 the winter. On 26/27 farms, during the summer, all adult cattle were released for grazing during the daytime and housed only at night. One farm housed cattle throughout the year, 155 using two different sheds, one for winter and one for summer. The study started in late winter 156 (March) and continued through to summer (June). Day 0 sample collection and vaccination 157 was undertaken on 9 th to 11 th of March. On most farms, animals were housed for the first 158 three sample collections (days 0, 14 and 30), but on days 60 and 90 all farms had started 159 summer grazing except for the farm which housed their cows throughout the year.
160
Sample collection 161
Blood samples were collected on day 0 before vaccination and on days 14, 30, 60 and 90 162 after vaccination. To avoid grazing times, samples were collected from 6 am to 11 am and 163 from 4 pm to 8 pm; approximately 10 mL of blood was collected via jugular venepuncture 164 into plain vacutainers (BD, India). After collection, blood samples were allowed to settle for 165 10 to 15 minutes before moving on to the next farm.
166
For the blood samples collected in the morning, serum separation was undertaken during the 167 afternoon (1 pm-3 pm), while for those collected in the evening, serum separation was done 168 at night (9 pm-11 pm). Blood samples were centrifuged at 1000g for 15 to 20 minutes, and 169 serum transferred to screw-capped cryovials for storage at -20C (25). Duplicate aliquots 170 were collected for each sample. Each sample from a cow was assigned a sample 171 identification number (order of sampling) so that the laboratory was blinded to the treatment 172 group.
173
At the end of the sample collection period (i.e. late June), one serum aliquot per cow was transported by air to the OIE/EU/WHO reference laboratory on Rabies, Nancy in France for analysis.
Seroneutralization test 178
The serum samples were analysed for VNA titres using the standard fluorescent antibody 179 virus neutralisation test (FAVN) protocol as described by Cliquet et al. (26) .Briefly, the test 180 was performed on 96 wells microtiter plate with serial threefold dilutions of the positive, μL of diluted BHK-21 cell suspension with concentration of 4 X 10 5 cells/mL was added to 190 each well and further incubated at 36°C±2°C in a 5% CO2 humidified incubator for 48 hours.
191
The cell culture medium was then discarded and the microplates rinsed once in phosphate 192 buffer solution and then in 80% acetone. The microplates were then fixed in 80% acetone at 193 room temperature for 30 minutes which was drained off and air dried at room temperature.
194
Fluorescein isothiocyanate conjugate was used for staining microplate wells. The wells were 195 read using a fluorescent microscope (between 100X and 125X magnifications) and examined 196 for the presence or absence of fluorescent cells. It is an "all or nothing" reading therefore the the Akaike information criterion. These analyses were undertaken using SPSS statistics 24 211 (IBM, USA).
212
Further analysis was then undertaken to include factors other than treatment and time, and to 213 establish; 1) variables that affected the probability of response to vaccination (titre ≥0.17 214 IU/mL), and 2) variables that were associated with strength of protection given a response.
215
An intercept-only repeated measures multilevel (including village, farm and cow levels) 216 linear mixed model was fitted using log VNA titre as an outcome variable to determine 217 whether the village and farm level random effects needed to be included. Once it was 218 confirmed that they did not, a generalised estimating equation (GEE) model (31) with a 219 binomial error distribution was then used to model the probability of response (titre ≥0.17 220 IU/mL). Initially several univariable models were created, with age, BCS, sex, breed and herd 221 size. For this analysis BCS was recoded as 2, 2.5 and ≥3, herd size as 1-6, 7-8 and 9-11, and 222 age as ≤1.5-year old, 2-5 years old and ≥ 6-year old to create categories with even group model had p ≤0.05, except that a confounder that changed coefficients or standard errors of 226 independent variables by ≥20% was forced into the model, regardless of its p-value.
227
Independent variables that had been removed were then added back into the model one by 
234
Results
235
Proportion of animals that responded to the vaccination 236 On day 0, all tested cattle had titres <0.17 IU/mL. Based on this cut-off point, the overall 237 response rate for the intramuscular group was 98% and for the intradermal group 96% (Table   238 1). The overall proportion of the cattle with VNA titre ≥ 0.17 IU/mL between the two 239 vaccination groups was not affected by route of vaccination (p=0.35) or the interaction 240 between vaccination route and time after vaccination (p=0.31). However, compared to Day 0, 241 the proportion of vaccinated cattle with a titre >0.17 IU/mL was greater on all other sample 242 days (p<0.001); this was also the case for days 14 and 30 compared to day 90 (p≤0.02). As with the proportion of cattle with a titre ≥0.17 IU/mL, there was no effect of vaccination 
243
260
For the 0.5 IU/mL threshold, no effect of vaccination route on proportion of titres ≥0.5 261 IU/mL was found (p= 0.538). However, both the interaction between vaccination route and 262 time and time alone were significant at the 4% level (p=0.039 and <0.001, respectively). On 263 both day 14 and day 30 the proportion of cattle with a VNA titre ≥ 0.5 IU/mL was lower in 264 the intradermally vaccinated group than in the intramuscularly vaccinated group (Table 3) . 2) . In both groups, VNA titres were higher after vaccination throughout 270 the study period than before vaccination (p<0.001 for all comparisons), with the mean VNA 271 titres of both groups peaking on day 30. The decline in titres after the peak was more marked 
265
Effect of cow and farm level factors on response to vaccination 284
The GEE modelling process found that there was a significant interaction between route and This is the first study to compare the efficacy of intramuscular and intradermal routes of 299 rabies vaccination in cattle in Bhutan under field conditions. It is also, as far as the authors 300 are aware, the first study of intradermal vaccination against rabies in cattle to use more than 301 10 cattle per treatment group. The study was designed as a non-inferiority trial with the aim 302 of confirming whether the mean VNA titres produced by intradermal vaccination were no 303 more than 0.5 IU/mL lower than the titres produced by the standard intramuscular 304 vaccination. In addition, three thresholds of vaccination response were used in order to 305 further compare the response of the two vaccination routes.
306
The geometric mean VNA production by intradermal vaccination using 1/5 (0.2mL) of the Inhibition Test (RFFIT). They reported intradermal vaccination produced titres equivalent to 321 those produced by the intramuscular route despite using 1/5 of the dose (VNA titre in IU/mL;
322
Zero day-0.07 for IM and ID, 14 th day 0.89 for IM and 0.6 for ID; 28 th day 2.81 for IM and 323 2.54 for ID). However, in addition to being a small study (8 cattle per treatment group), this 324 was a post-exposure prophylaxis study, so cattle were vaccinated on days 0 ,3, 7, 14 and 28, 325 significantly increasing the chance of a response. Furthermore, as a post-exposure study with 326 no untreated controls, it is not clear whether any of the response was due to exposure to wild-327 type virus.
328
A more directly comparable study is that by Benisek et al. (2006) (20) Benisek et al. (20) was different from that seen in this study. The mean VNA titres in their 339 study were still >0.5 IU/mL 180 days after intramuscular vaccination compared to this study 340 in which mean VNA titres after intramuscular vaccination were <0.5 IU/mL within 90 days.
341
Furthermore, the proportion of cattle with a titre ≥0.5 IU/mL on days 14 and 30 in the 342 intramuscularly vaccinated group in this study were lower than the WHO targets for tissue 343 culture rabies vaccine of almost 100% (32).
344
The results of this study also seem to be in contrast to the undoubted efficacy of intradermal 345 rabies vaccination in humans (17). However, in humans pre-exposure vaccination is a 346 multidose regimen that requires three to four doses of vaccine (33, 34) . Furthermore, the 347 results of the current study are consistent with the statement made by WHO (30) that 348 'antibody titres are higher and more sustained after intramuscular injection'.
349
One potential issue is that intradermal vaccination is more difficult, so some vaccines could 350 have been incorrectly administered into adipose or subcutaneous tissue. However, >90% of 351 vaccinations were recorded as definitively going intradermally, and the titres of the nine 352 cattle in which this was not the case were not significantly different from those which did 353 (data not shown). Another potential issue was that as there was no licensed rabies vaccine for 354 intradermal use in cattle, a 10 mL vaccine vial was used for this study. study.
374
In this study there was a significant interaction between vaccination and age with younger 375 animals (age <2) having an increased chance of response (titre ≥0.17 IU/mL) when given 376 intradermal rather than intramuscular vaccination and having higher titres when they 377 responded. Further research is required to better establish whether the apparent association 378 between age and response to intradermal vaccination is clinically significant.
379
Even disregarding the impact of age the effect of route on VNA titres may not have been as 380 great as suggested in Figure 2 . When the cut-off for a protective titre was reduced from ≥0.5 381 to ≥0.24 IU/mL, there was no difference in response between the two routes and geometric 382 mean VNA titres in both groups were ≥0.24 IU/mL throughout the duration of the study 383 following vaccination. This cut-off point was chosen based on the vaccination and challenge studies conducted in cattle, dogs, cats (27, 28, 36, 37) and foxes (29). Côrtes et al. (28) 385 reported a protection rate of 80% in cattle with titre ≥0.24 IU/mL when challenged with a 386 virulent strain of rabies virus. However, there was only a 5% increase in the proportion 387 protected with titre ≥ 0.5 IU/mL.
388
Thus, although a higher VNA titre is preferred, any seroconversion following vaccination 389 indicates some degree of protection (27, 37) , particularly against natural infection, which is 390 usually less severe than the experimental infection used to set thresholds (27, 38) . However, 391 much of this is based on data from dogs, which are reservoir hosts and there may therefore be 392 a certain degree of host-virus adaptation that reduces the risk of infection in dogs compared 393 to dead end hosts such as cattle (27).
394
Thus, the results of this study do not support the routine use of intradermal vaccination of 395 cattle using the Raksharab vaccine at a dose rate of 0.2 mL, except, perhaps in cattle <2 years 396 old. Further studies are needed, in particular on the use of a booster vaccination 60 days after 397 primary vaccination, or on the use of a higher dose than the 0.2 IU/mL used in this study. The 398 latter is likely to have lower costs and be more feasible, and increasing the intradermal dose 399 is easier in cattle than humans as cattle skin is relatively thick and it is therefore easier to 400 administer larger quantities of vaccine at one site (39).
401
Conclusion
402
Intradermal vaccination induced protective titres (≥ 0.5 IU/mL) in 71% of cattle, despite 403 using 1/5 of the recommended dose. However, the proportion of cattle with a protective titre 404 was significantly lower than for cattle given the standard dose (1mL) intramuscularly (71 vs 405 89%). In addition, mean antibody titres in the intradermally vaccinated cattle were 406 significantly lower than the intramuscularly vaccinated cattle on days 14 and 30 post 407 vaccination. Intradermal vaccination using 1/5 dose was inferior to intramuscular vaccination using the standard dose. However, the antibody responses obtained in this study were good 409 enough to support further testing of intradermal vaccination with an increased dose. 
